Morphic Holding (MORF) Eli Lilly Merger Issues Case

• $MORF stockholder filed a claim against Morphic Holding to block its merger with Lilly until issues are fixed or, if it proceeds, to seek damages for losses.

• Morphic investors can join this case to be notified about potential recovery.

Case details:

On July 8, 2024, Morphic and Lilly announced a merger agreement.

On July 19, 2024, Lilly began a tender offer to buy Morphic, which will be finalized on August 15, 2024, making Morphic a part of Lilly.

After that, Morphic filed a misleading Recommendation Statement with the SEC, falsely advising Morphic shareholders to tender their shares:

• The Statement notes that Nanda, employed by Lilly, missed the Board’s discussions, but it overlooks the conflict of interest from Lilly’s ties with Polaris, where Nashat is an executive partner.

• On July 5, 2024, Evercore disclosed its ties to Lilly, but the Statement does not clarify if Evercore worked for or was paid by Lilly in the past two years.

Based on these events, a $MORF stockholder filed a claim to block the tender offer and merger until issues are resolved or, if the merger proceeds, to seek damages for losses.